Virtual Library
Start Your Search
Renwang Liu
Author of
-
+
P3.02 - Biology/Pathology (ID 620)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-097 - Clinicopathological Features and Genetic Landscape of Pulmonary Large Cell Carcinoma under 2015 WHO Classification of NSCLC (ID 7461)
09:30 - 09:30 | Presenting Author(s): Renwang Liu
- Abstract
Background:
Pulmonary large cell carcinoma (LCC) was re-defined by 2015 WHO classification of non-small cell lung cancer (NSCLC) by excluding the tumors with adenocarcinoma, squamous and neuroendocrine features. The clinicopathological features and genetic landscape of pulmonary large cell carcinoma (LCC) with new classification were barely investigated.
Method:
Twenty-four LCC patients previously diagnosed under WHO 2004 criteria at Tianjin Medical University General Hospital were collected and re-classfied by 2015 WHO classification criteria. The specimen with more than 1% positivity of TTF-1/napsin A and 10% positivity of p40/p63/ CK5/6 expression was excluded from LCCs under WHO 2015 criteria in this study. The specimens with CgA and Syn positivity, the feature of neuroendocrine tumor, were excluded too. The genetic analysis was performed by the next-generation sequencing (NGS) of 46 cancer-related genes on the newly re-classified LCCs. The correlation of clinicopathological and genetic data was further analyzed on these samples.
Result:
All 8 patients re-defined as LCCs under WHO 2015 criteria were male and 7 patients were smokers. None of significant difference was found between the LCCs patients and excluded patients under WHO 2015 criteria in terms of age, gender, smoking status, primary site and TNM staging. Although lower OS time was presented in LCCs under WHO 2015 criteria compared with the excluded ones, no significant difference was detected between these two groups (LCC under WHO 2015 criteria vs excluded specimens = 698.75±62.83 vs 1301.03 ±245.40 days, P=0.738). Ten of 46 candidate genes including EGFR, KRAS, TP53, KIT, PIK3CA, PTEN, IDH1, APC, ATM and BRAF were detected in all 24 specimens. Four of all 8 LCC patients under WHO 2015 criteria presented TP53 mutation and two showed concurrent TP53 and KRAS mutations. None of any somatic mutation was detected in the rest 4 of 8 LCCs. LCCs under 2015 criteria showed a lower heterogeneity and lower incidence of TP53 mutation compared to the with excluded specimens (TP53 mutation: LCCs vs excluded specimens=4/8 vs 15/16, p=0.015; Detected mutations: LCCs vs excluded specimens = 2/46 vs 10/46, p=0.030).
Conclusion:
LCCs re-classified by the new criteria remain the features of higher incidence in male and tobacco exposure. No significant difference change in terms of other clinical characteristics. The lower heterogeneity of somatic mutation in LCCs under WHO 2015 criteria might reflect the precision and uniformity of the new classification on the genetic level.
